Companies marketing integral drug-device combination products who want to make changes to the medicinal component might need to obtain a new/updated opinion from a notified body (NB) about the product’s device portion, the European Medicines Agency has clarified in a newly revised Q&A document.
Changes to the medicinal product, such as an extension of indication, new strength or new pharmaceutical form, may have an impact on the safety or performance of